Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly projects 32% revenue growth for 2025, fueled by incretin expansion and new launches. 1mo. ... Earnings per share for 2025 are projected at $22.50 to $24.00.

Eli Lilly and Company (NYSE:LLY) Number of Hedge Fund Holders In Q2 2024: 100. Projected EPS Growth Rate: 50.6%. Eli Lilly and Company (NYSE:LLY) is a mega pharmaceutical company that sells ...

Eli Lilly not only beat earnings per share (EPS) expectations with a non-GAAP EPS of $2.58 compared to the analysts' consensus figure of $2.47, but also showcased an impressive revenue increase.

TD Cowen analyst Steve Scala has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Steve Scala has given his Buy rat ...

Eli Lilly and Company (NYSE:LLY) last week reported its latest yearly results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations.

Summary. Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of ...

Eli Lilly and Company LLY reported second-quarter 2023 adjusted earnings per share of $2.11, which beat the Zacks Consensus Estimate of $1.98.

This compares with the company's previous outlook for revenue in the range of $42.4 billion to $43.6 billion and earnings per share of $13.50 to $14.00. Is Eli Lilly stock a buy, sell or hold?